71 Results

People

  1. Palomba
    Palomba
  2. Batlevi
    Batlevi
  3. Park
    Park
  4. Brentjens
    Brentjens
  5. Sauter
    Sauter
  6. Zelenetz
    Zelenetz
  7. Intlekofer
    Intlekofer
  8. Shah
    Shah
  9. Noy
    Noy
  10. Hamlin
    Hamlin

Groups

  1. Center for Hematologic Malignancies (71)
  2. Department of Medicine (71)
  3. GSK Faculty (71)
  4. Hematologic Malignancies Research (71)
  5. Hematologic Malignancies, Division of (71)
  6. Lymphoma (71)
  7. Adult Leukemia (47)
  8. Survivorship Research (42)
  9. Epidemiology and Biostatistics (39)
  10. Bone Marrow Transplant (37)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Maria Palomba"
Formats
  1. Meeting Abstract (54)
  2. Journal Article (17)
Groups
  1. Center for Hematologic Malignancies (71)
  2. Department of Medicine (71)
  3. GSK Faculty (71)
  4. Hematologic Malignancies Research (71)
  5. Hematologic Malignancies, Division of (71)
  6. Lymphoma (71)

More Groups

People
  1. Maria Palomba (71)
  2. Jae Park (37)
  3. Connie Batlevi (35)
  4. Renier Brentjens (30)
  5. Andrew Zelenetz (27)
  6. Craig Sauter (27)

More People

Years
  1. 2023 (14)
  2. 2022 (7)
  3. 2021 (6)
  4. 2020 (10)
  5. 2019 (13)
  6. 2018 (6)

More Years

Publications
  1. Blood (37)
  2. Blood Advances (6)
  3. Hematological Oncology (6)
  4. Biology of Blood and Marrow Transplantation (4)
  5. Journal of Clinical Oncology (2)
  6. Nature Medicine (2)

More Publications

Publishers
  1. American Society of Hematology (43)
  2. Nature Publishing Group (7)
  3. Wiley Blackwell (6)
  4. Elsevier Inc. (5)
  5. American Society of Clinical Oncology (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (71)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations
    Journal Article

    Maclachlan, K. H.; Bagratuni, T.; Kastritis, E.; Ziccheddu, B.; Lu, S.; Yellapantula, V.; Famulare, C.; Argyropoulos, K.; Derkach, A.; Papaemmanuil, E.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
    Journal Article

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K. V.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save